
==== Front
Acta Diabetol
Acta Diabetol
Acta Diabetologica
0940-5429
1432-5233
Springer Milan Milan

38717484
2286
10.1007/s00592-024-02286-1
Original Article
Reduced expression of central innate defense molecules in pancreatic biopsies from subjects with Type  1 diabetes
http://orcid.org/0000-0002-5489-6688
Tegehall Angie angelica.tegehall@igp.uu.se

1
Ingvast Sofie 1
http://orcid.org/0000-0002-1057-7095
Krogvold Lars 2
http://orcid.org/0000-0002-6952-9899
Dahl-Jørgensen Knut 23
http://orcid.org/0000-0002-8524-9547
Korsgren Olle 1
1 https://ror.org/048a87296 grid.8993.b 0000 0004 1936 9457 Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden
2 https://ror.org/00j9c2840 grid.55325.34 0000 0004 0389 8485 Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
3 https://ror.org/01xtthb56 grid.5510.1 0000 0004 1936 8921 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Managed by Piero Marchetti.

8 5 2024
8 5 2024
2024
61 9 11171127
6 9 2023
6 4 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Aims/Hypothesis

Defensins play a crucial role in the innate immune system's first defense against microbial threats. However, little is known about the defensin system in the pancreas, especially in relation to Type 1 diabetes. We explore the expression of defensins in different disease stages of Type 1 diabetes and correlated obtained findings to the degree of inflammation, providing new insights into the disease and the innate immune system.

Material and methods

Pancreases from non-diabetic human organ donors of different age groups and donors with Type 1 diabetes with different disease duration were examined. Sections from head, body and tail of the pancreas were stained for eight different defensins and for immune cells; CD3+, CD45+, CD68+ and NES+ (granulocytes).

Results

In non-diabetic adult controls the level of expression for defensins Beta-1,Alpha-1, Cathelicidin and REG3A correlated with the level of inflammation. In contrast, individuals with Type  1 diabetes exhibit a reduction or absence of several central defensins regardless of the level of inflammation in their pancreas. The expression of Cathelicidin is present in neutrophils and macrophages but not in T-cells in subjects with Type 1 diabetes.

Conclusions

Obtained findings suggest a pancreatic dysfunction in the innate immune system and the bridging to the adaptive system in Type 1 diabetes. Further studies on the role of the local innate immune system in Type 1 diabetes is needed.

Keywords

Biopsy
Defensins
Etiopathology
Innate immunity
Pancreas
Type 1 diabetes
http://dx.doi.org/10.13039/501100004359 Vetenskapsrådet http://dx.doi.org/10.13039/100015758 Novo Nordisk Pharma http://dx.doi.org/10.13039/501100006415 Stiftelsen Familjen Ernfors Fond Nils eric holmstens forskningsstiftelsehttp://dx.doi.org/10.13039/501100004973 Barndiabetesfonden http://dx.doi.org/10.13039/501100008550 Diabetesfonden http://dx.doi.org/10.13039/501100009788 Sten A Olssons Stiftelse för Forskning och Kultur Uppsala UniversityOpen access funding provided by Uppsala University.

issue-copyright-statement© Sanofi-Aventis S.p.A. 2024
==== Body
pmcIntroduction

Defensins are small molecules (2–5 kDa) that play an important role in the innate and adaptive defence system. They belong to a large family of antimicrobial peptides of ancient conservation. Humans express two subfamilies, Alpha- and Beta-defensins which differ in the length of cysteine peptide segments and pairing of the cysteines by disulphide bonds [1–3]. The Alpha family is most often regulated on the secretory level by release from granules in neutrophils or Paneth cells upon a trigger in the environment, while the Beta family is regulated transcriptionally [1, 4, 5]. Epithelial cells in various tissues consistently express certain Beta-defensins, such as hbD-1 [5, 6]. Inflammation or exposure to bacterial toxins in the environment can lead to modulation and increase of Beta-defensins [6, 7].

Defensin families differ in structure and regulation, they also differ in their antimicrobial action and modulation of the immune system. Beta-defensins have antimicrobial, anti-viral and chemotactic properties [8] and are considered to have a role in the adaptive immune response. The antimicrobial effect has predominantly been shown against gram negative bacteria, such as Escherichia coli [9]. Alpha-defensins exhibit potent antimicrobial activity against both gram-negative and gram-positive bacteria by membrane disruption. Additionally, they have been shown to inhibit the adhesion of enveloped viruses to host cells and prevent uncoating of capsid viruses [5]. Thus far, there has been no description of a link to the adaptive system for the Alpha-defensin family.

Defensins can also drive an inflammatory process into a chronic pathological state involving other inflammatory mediators and the adaptive immune system [10]. Psoriasis and Crohn's disease are two clinically significant examples where altered defensin expression plays an important role [11].

Although defensins have been extensively researched in the skin, gut, and oral cavity, their function in the pancreas remains largely unknown [12, 13]. Several studies describe ongoing inflammation of the pancreas in subjects with recent onset Type 1 diabetes [14–17]. There is also an association between bacterial infections during infancy and a high risk of developing islet-autoantibodies and Type  1 diabetes [18]. Translocation of bacteria and viruses from the duodenum to the pancreas could trigger the activation of innate inflammatory immune response [17, 19]. The inflammatory response driven by infectious agents has been suggested as triggers for Type 1  diabetes [20, 21]. The aim of this study was to characterize the expression of different defensins in non-diabetic organ donors of different ages as well as in donors with Type 1 diabetes with different disease duration to examine a tentative role in Type 1 diabetes.

Materials and methods

Ethics

The research work conducted using human tissue followed guidelines outlined in the Declaration of Helsinki. Pancreatic tissue was procured from organ donors, and consent to use it for research purposes was obtained from the next of kin either verbally by the attending physician or from an online database. Procedures were fully documented according to Swedish law and regional standards. The present study utilized pancreatic samples from patients who were part of the DiViD study, approved by The Norwegian Governments Regional Ethics Committee. Prior to participation, patients were provided comprehensive oral and written information from the diabetologist and surgeon separately.

Human pancreatic samples

Biopsies from 41 human pancreases were included in the study, divided into five different groups. One donor died at onset, four living patients (DiViD-study) [22], 13 organ donors with longstanding Type 1 diabetes, 19 non-diabetic organ donors and four organ donors under five years of age (Table 1). The adult non-diabetic individuals were matched to the subjects with Type 1 diabetes for age, sex and BMI. Three parts of the pancreas, head, body and tail, was chosen from each donor where this was possible. Table 1 Detailed list of antibodies used

Antibody	Clone	Dilution	Control tissue	
Anti α-1 (Abcam)	–	1:200	Human spleen	
Anti β-1 Abcam)	M11-14b-D10	1:100	–	
Anti β-2 (Abcam)	–	1:500	Human tonsil	
Anti β-3 (Abcam)	–	1:200	–	
Anti-Cathelicidin (Abcam)	–	1:1000	Human spleen	
Anti-GP2 (Abcam)	GP2/1712	1:200	Human pancreas	
Anti-Neutrophil-4 (Abcam)	–	1:50	Human spleen	
Anti-REG3A (Abcam)	–	1:100	Human duodenum	
Anti-CD45 (Agilent)	2B11 + PD7/26	1:75	Human spleen	
Anti-CD68 (Agilent)	KP1	1:50	Human spleen	
Anti-CD3 (Abcam)	265-3kl	1:50	Human spleen	
Anti-NES (Invitrogen)	F7.2.3B	1:25	Human spleen	

The organs were procured within the Nordic Network for Clinical Islet Transplantation.

Immunohistochemistry

Formalin-fixed and paraffin-embedded tissue were cut into 6 µm sections, consecutive sections were processed and labeled using a standard immunoperoxidase technique. All antigens were unmasked by heat-induced epitope retrieval using pH 6.0 or pH 9.0 according to recommendations by the manufacturer. Primary antibodies specific for CD45, insulin, synapthofysin and eight different defensin molecules were used (Table 2). Bound antibodies were visualized using Dako EnVision or EnVision DuoFLEX Doublestain system (Agilent, California, USA) and diaminobenzidine-based substrate (Agilent, California, USA). Sections were counterstained with hematoxylin, dehydrated, mounted and analyzed by light microscope (Leica, Germany). Positive controls were running in parallel with each defensin and isotype mAbs were used as negative controls. For double staining, Cathelicidin and immune cells antibodies toward CD45, CD68, NES and CD3 were used and visualized by immunofluorescence. Confocal microscope Zeiss LSM700 (Zeiss,Germany) and software Zen black 3.0 SR (Zeiss, Germany) was used to analyze the slides. Table 2 Donor characterization

Variable	Non-diabetic donors	Donor who died at onset of Type-1 diabetes	Donors with recent onset Type-1 diabetes	Donors with longstanding Type-1 diabetes	
Number of subjects	23	1	4	13	
Duration of Type-1 diabetes (weeks)	N/A	0	3–9	 > 200	
Age	34.5 ± 21.9	29	28.5 ± 4.8	44.8 ± 20.4	
Female	10	–	2	7	
Male	13	1	2	7	
Body mass index (kg/m2)	24.3 ± 5.22	24.2	22.8 ± 2.2	25.7 ± 5.12	
Hba1c	37.5 ± 3.5	95	72.75 ± 4.32	73 ± 25	
N/A not applicable

Analysis and statistical analysis

All slides were analyzed by two independent investigators blinded with regard to donor type. The analysis was performed as a semi-quantitative method using a standard four scale IHC score system (0,1,2,3). The IHC score was set by combining three parameters. (1) staining intensity, (2) proportion of stained pancreatic area, and (3) staining pattern. The staining was evaluated with regard to cytoplasmic and nucleic expression of the various defensins in exocrine and endocrine pancreas, as well as in blood vessels, connective tissue, ducts and adipose tissue of the pancreas. Immune cells were analyzed by comparing overlay of staining between Cathelicidin and immune cell staining.

Statistical analysis

A mean IHC score for each donor was calculated from the examined sections.

The mean IHC score for each subject was used in the box-plot figures and statistical analysis. Statistical significance between groups were calculated by performing a Kruskal–Wallis analysis followed by Dunns multiple comparisons. The significance level was < 0.05 by using Graphpad prism 9 software.

Results

Beta-defensins

The three Beta-defensins had their own individual staining pattern. Beta-1 was observed as a cytoplasmic staining pattern in the exocrine compartment with varying level of expression in adult non-diabetic subjects (Fig. 1d). The most common IHC score was 0 for endocrine tissue and IHC score 2 for exocrine tissue. The same expression pattern was observed in the child group. In groups with Type 1 diabetes subjects most biopsies were negative in both endocrine and exocrine tissue (Fig. 1e, f), except for a few donors with a low-grade positive staining in the cytoplasm of the exocrine tissue (mean IHC score = 0.44). Beta-1 expression in exocrine tissue in subjects with Type 1 diabetes was significantly reduced when compared with non-diabetic subjects (p-value ≤ 0.05, Fig. 2a).Fig. 1 a Representative staining of Alpha-1 in an adult without Type 1 diabetes. A patchy cytoplasmatic staining pattern of varying intensity can be seen in the exocrine pancreas. The endocrine tissue shows low-grade positive cytoplasmatic staining. b Expression in a DiViD patient for Alpha-1 show negative expression in both exocrine and endocrine tissue. c Staining of a donor with longstanding Type 1 diabetes of defensin Alpha-1 show some areas of a low-grade cytoplasmatic staining in the exocrine pancreas and no staining in endocrine tissue. d Staining of Beta-1 in an adult donor without diabetes show a homogenous cytoplasmatic staining of both exocrine and endocrine tissue. e In a subject with recent onset Type 1 diabetes and f in a subject with longstanding Type 1 diabetes no expression of Beta-1 could be found in exocrine and endocrine tissue. g Staining of REG3A in an adult donor without diabetes show a high intensity patchy staining in the cytoplasmic compartment of the exocrine pancreas. Endocrine tissue was mostly negative. h Staining for defensin REG3A in DiViD patients show a low-grade patchy staining in the cytoplasmic compartment of the exocrine tissue with smaller clusters of cells with more intense staining. The endocrine tissue was negative. i Staining for REG3A in a donor with longstanding Type 1 diabetes show a similar staining pattern as in subjects with recent onset Type 1 diabetes but with larger areas of exocrine cells showing an intense cellular staining. Endocrine tissue was mostly negative. Original magnification × 20

Fig. 2 Each data point represents the mean value of the IHC score of the three pancreatic regions in one donor in endocrine and exocrine tissue, respectively. The donors were divided into different groups depending on disease status, non-diabetic adults (n = 19), non-diabetic children (n = 4), Type 1 diabetes donor that died at onset (n = 1), Type 1 diabetes recent onset (DiViD patients) (n = 4) and Type 1 diabetes longstanding donors (n = 13). The IHC scores for defensin Beta-1 are shown in a, Beta-2 in b and Beta-3 in c. Statistically significant differences are shown in each figure using Kruskal–Wallis test and Dunns test for multiple comparisons p values were non-significant > 0.05 for all groups

The staining pattern of Beta-2 displayed both a cytoplasmatic and nuclear staining with some variation in both the exocrine (mean ICH score = 1.64) and endocrine (mean ICH score = 1.83) tissue. No statistically significant difference (p =  > 0.05) was observed (Fig. 2b) between subjects with Type 1 diabetes and non-diabetic subjects.

Beta-3 showed a cytoplasmic expression pattern in the exocrine pancreas with little variation between groups. The endocrine tissue had an expression pattern of a low-grade cytoplasmic positive staining in biopsies from the adult non-diabetic control group, the child group and the Type 1 diabetes recent onset patients (mean IHC score=0.90). In the Type 1 diabetes longstanding donors and the donor that died at onset almost all biopsies were negative (IHC score = 0) except for a few donors with a low-grade positivity in just one part of the pancreas. In subjects with longstanding Type 1 diabetes a significant reduction in Beta-3 expression was found when compared with non-diabetic controls (p ≤ 0.05, Fig. 2c).

Blood vessels, connective tissue, ducts and adipose tissue were negative for the staining in all donors for all three Beta-defensins.

Alpha-defensins

Defensin Alpha-1 was observed with a patchy cytoplasmatic staining pattern in exocrine parenchyma in the adult non-diabetic control group (Fig. 1a). A dichotomic expression in endocrine tissue was found. Many subjects with no expression and others with a cytoplasmatic and nucleic expression (mean IHC score = 0.94). In the child group the same expression pattern was observed but with a lower grade of staining, mean IHC score of 1 (exocrine tissue), mean IHC score of 0 (endocrine tissue), respectively. Almost all Type 1 diabetes donors were negative (IHC score = 0) in both endocrine and exocrine tissue (Fig. 1b, c). Some donors with longstanding Type 1 diabetes had a low-grade positivity in occasional biopsies (mean IHC score = 0.09). Statistically significant differences were found in both endocrine and exocrine pancreas between non-diabetic adults and subjects with recent onset and longstanding Type 1 diabetes (p ≤ 0.05, Fig. 3a). Blood vessels, connective tissue, ducts and adipose tissue were negative for the staining in all donors.Fig. 3 Each data point represents the mean value of the IHC score of the three pancreatic regions in one donor in endocrine and exocrine tissue, respectively. The donors were divided into different groups depending on disease status, non-diabetic adults (n = 19), non-diabetic children (n = 4), Type 1 diabetes donor that died at onset (n = 1), Type 1 diabetes recent onset (DiViD patients) (n = 4) and Type 1 diabetes longstanding donors (n = 13). The IHC scores for defensin Alpha-1 are shown in a and defensin Neutrophil-4 in b. Statistically significant differences are shown in each figure using Kruskal–Wallis test and Dunns test for multiple comparisons p values were non-significant > 0.05 for all groups

Defensin Neutrophil-4 had a cytoplasmatic expression with great individual variation with a seemingly lower expression in exocrine tissue (mean IHC score = 1.09) when compared with endocrine (mean IHC score = 1.84) tissue (Fig. 3b). Positive granular cytoplasmatic staining, with variation between donors, could also be observed in some exocrine and endocrine cells as well as in blood vessels. Nuclear staining of cells in blood vessels was also observed. Connective tissue, ducts and adipose tissue were negative for the staining in all donors. No statistically significant differences could be observed (p ≥ 0.05) (Fig. 3b).

Other defensins

Cathelicidin was expressed as a homogenous staining in the cytoplasmic compartment in exocrine tissue in the adult non-diabetic control group (Fig. 4a). Occasional single cells with a more pronounced cytoplasmatic staining were observed in the exocrine tissue. Two control donors showed a high number of this single cell staining. The endocrine tissue was homogeneously stained in the cytoplasmic compartment (mean IHC score = 2.75). The exocrine parenchyma in the child group showed a low-grade cytoplasmic staining (mean IHC score = 0.58), also a few scattered single cells with high level of expression was found in some of the children. In the endocrine tissue the expression varied between donors from IHC score = 0 to a homogenous low-grade cytoplasmic staining (mean IHC score = 0.58).Fig. 4 a Representative IHC staining of Cathelicidin in an adult without Type 1 diabetes show a cytoplasmatic homogenous staining in both exocrine and endocrine tissue. The staining in the endocrine pancreas was markedly more intense than in the exocrine tissue. b No Cathelicidin expression could be detected in the exocrine and endocrine tissue in the donor that died at onset of Type 1 diabetes. However, a large amount of intensely positive stained single cells scattered throughout the pancreatic tissue was observed. c Immunofluorescence staining of Cathelicidin (green) and CD3 (red) in a DiViD patient with an islet with insulitis in the center of the slide as well as in a subject with longstanding Type 1 diabetes in d  with ongoing inflammation in the pancreas, show no co-staining for Cathelicidin (green) and CD3 (red). Original magnification × 20

The donor that died at onset had a negative cytoplasmic expression in both endocrine and exocrine tissue. However, numerous positive single cells in the exocrine tissue was found (Fig. 4b). The recent onset patients stained low-grade positive in the cytoplasmic compartment (mean IHC score = 1) of the exocrine tissue. In donors with positive single cells, the cells were scattered in some but not in other lobes of the pancreas. These cells could also be found accumulating adjacent to some islets. The endocrine tissue was positive in most islets (mean IHC score = 1.75), but negative islets (IHC score = 0) did occur in all four donors.

The staining pattern in subjects with longstanding Type 1 diabetes varied depending on age. In the age group 15–25 years (n = 4) the exocrine tissue showed negative or low-grade positive staining in the cytoplasmic compartment (mean IHC score = 0.83). Three donors also had positive single cell staining in the exocrine tissue of varying degrees as described above. The endocrine tissue stained homogenously in the cytoplasmic compartment (mean IHC score = 1).

In the age group 25–55 years two of the three donors had a homogenous staining of the cytoplasmic compartment (mean IHC score = 1.33) in the exocrine parenchyma and with an even higher intensity in the islets (mean IHC score = 3). Varying numbers of high intensity positive single cells was found in both donors. The third donor was negative in both the exocrine and endocrine parenchyma. Age group 55–70 years all donors exhibited a positive homogenous staining of the cytoplasmic compartment of both exocrine (mean ICH score = 2.25) and endocrine tissue (mean IHC score = 1.66). All donors also displayed varying numbers of scattered positive single cells throughout the tissue. A statistically significant reduction in expression of Cathelicidin in both exocrine and endocrine pancreas were found in children when compared with adults (p ≤ 0.05, Fig. 5a). Also, expression of Cathelicidin in endocrine pancreas was reduced in subjects with longstanding Type 1 diabetes. No positive staining in blood vessels, connective tissue, ducts or adipose tissue was found in any group.Fig. 5 Each data point represents the mean value of the IHC score of the three pancreatic regions in one donor in endocrine and exocrine tissue, respectively. The donors were divided into different groups depending on disease status, non-diabetic adults (n = 19), non-diabetic children (n = 4), Type 1 diabetes donor that died at onset (n = 1), Type 1 diabetes recent onset (DiViD patients) (n = 4) and Type 1 diabetes longstanding donors (n = 13). The IHC scores for Cathelicidin is shown in a, defensin GP2 in b and defensin REG3A in c. Statistically significant differences are shown in each figure using Kruskal–Wallis test and Dunns test for multiple comparisons p values were non-significant > 0.05 for all groups

The positive single cells were further investigated with IF staining for different immune cells. Cathelicidin stained positive in innate immune cells of the pancreas. In the donor that died at onset of Type 1 diabetes the scattered Cathelicidin+ cells co-stained with NES or CD68. No CD3 positive cells were found. In the recent onset group the few scattered Cathelicidin+ cells co-stained with CD68. CD3 cells were present in proximity to islets (insulitis), however no CD3+ cell co-stained with Cathelicidin (Fig. 4c). In subjects with longstanding Type 1 diabetes all the scattered Cathelicidin+ stained cells co-stained with CD68. CD3 positive cells was also present in the older donors but showed no co-staining with Cathelicidin (Fig. 4d).

The pancreatic marker GP2 was observed as a homogenous cytoplasmic staining of the exocrine pancreas in all individuals (mean IHC score = 2.17). However, in children and in subjects with Type 1 diabetes large areas of unstained exocrine tissue were found. Endocrine tissue, blood vessels, connective tissue, ducts and adipose tissue was negative for the staining in all donors. No statistically significant difference could be observed (p ≥ 0.05 Fig. 5b).

Defensin REG3A was expressed as a cytoplasmatic staining with a patchy appearance in the exocrine tissue that correlated with the local inflammation, expression in endocrine tissue was low-grade (mean IHC score = 0.25 Fig. 1g–i). In children and in subjects with recent onset Type 1 diabetes the expression was lower in exocrine tissue (mean IHC score = 0.12). In subjects with longstanding Type 1 diabetes the level of expression was slightly higher compared to adult non-diabetic individuals (mean IHC score = 1.02). Blood vessels, connective tissue, ducts and adipose tissue were negative for the staining in all donors. No statistically significant differences could be observed (p ≥ 0.05 Fig. 5c).

Inflammation in correlation to defensin expression

In non-diabetic adult controls the level of expression for defensins Beta-1, Alpha-1, Cathelicidin and REG3A correlated with the level of inflammation (Figs. 2a, 3a, 5a and c). Inflammation in diabetic donors at onset was more intense and affected larger areas of the exocrine pancreas when compared with that observed in non-diabetic subjects. Inflammation consisted mostly of CD45+ cells but also CD3+ cells were found both in the exocrine parenchyma and in the vicinity of islets; peri-insulitis. Even so, most donors with Type 1 diabetes expressed no or only low levels of defensins Beta-1 and Alpha-1 (Figs. 2a and 3a). No significant differences in expression of Cathelicidin were found between non-diabetic and Type 1 diabetic subjects. Except for donors with longstanding Type 1 diabetes whom had a lower expression of Cathelicidin in islets (Fig. 5a). Notably, a majority of these donors with high inflammation in their pancreas showed no expression of Cathelicidin.

Discussion

Herein we report a markedly reduced expression of central defensins belonging to different families in both exocrine and endocrine tissue of the pancreas in subjects with Type 1 diabetes as compared to non-diabetic controls. Moreover, we found a positive correlation in non-diabetic subjects between inflammation in both endocrine and exocrine tissue and expression of several of the defensins. Notably, this correlation was markedly reduced or even absent in subjects with Type 1 diabetes. Among the three beta-defensins expression of Beta-1 is of most importance against bacterial infections [23]. Beta defensins also modulate the adaptive immune response by promoting chemotactic activities for immature dendritic cells and memory T-cells [7, 24]. Expression of Beta-1 was reduced in subjects with Type 1 diabetes compared to non-diabetic adult controls. Glucose homeostasis seems to have an important role in controlling expression of Beta-1 [23, 25]. However, no difference in expression of Beta-1 could be observed between the Type 1 diabetes groups suggesting a reduced expression of Beta-1 in subjects with Type 1 diabetes per se.

The Alpha defensins are part of a major interplay between healthy gut homeostasis, microbiota and innate immune system. The defensin resides in granules which are released when bacteria is present [1]. Decreased expression of Alpha-defensins cause an imbalance of this intricate system which has been considered as a trigger for inflammatory events and has been reported in Crohn´s disease [26]. Similarly, decreased expression of Alpha-1 defensin in subjects with Type 1 diabetes was found.

Children and subjects with Type 1 diabetes also had a marked reduction in the expression of Cathelicidin when compared with non-diabetic adult controls. With increasing age and therefore longer duration of Type 1 diabetes the expression pattern changed. In the oldest subjects with the longest disease duration expression showed a similar staining pattern as non-diabetic adults. Expression of Cathelicidin was also found in macrophages and neutrophilic granulocytes scattered in the exocrine pancreas especially in the Type 1 diabetes subjects. T-cells in the insulitic lesions in subjects with recent onset Type 1 diabetes were negative. These findings are in agreement with previous reports on expression of Cathelicidin in granules of neutrophils and macrophages [27]. Cathelicidin is not a defensin per se, but it is classified as an antimicrobial peptide and has a wide range of immunomodulatory effects [28]. Expression of Cathelicidin is dependent on vitamin-D [29]. Several studies have implied a correlation between induced risk of Type 1 diabetes and vitamin-D deficiency [30, 31]. Vitamin-D also plays an important role in beta-cell function and development [29, 30, 32, 33].

The defensin REG3A showed a slightly lower expression in children and subjects with recent onset Type 1 diabetes when compared with non-diabetic adults. Notably, subjects with longstanding Type 1 diabetes on the other hand had a slightly higher expression than non-diabetic adults. REG3A has been reported in several studies to have a protective role for beta-cells when overexpressed [34–36]. REG3A has also been shown to be altered by mild hyperglycemia [37]. Even if no statistically significant differences could be found, the findings presented support the view that islets in subjects with Type 1 diabetes suffer from a relative deficiency of REG3A [34–37].

Defensins have an important role in regulating inflammation and acquired immunity. In non-diabetic donors a correlation between pancreatic inflammation and expression of Beta-1, Alpha-1, Cathelicidin andREG3A were found. Inflammation in donors with Type 1 diabetes was more intense and affected larger areas of the exocrine pancreas when compared with that observed in non-diabetic subjects. Even so, expression of defensins remained low. Obtained findings implies that there could be a disturbance in how the innate immune system responds in individuals with Type 1 diabetes, tentatively causing prolonged local inflammation with negative effects on exocrine and endocrine homeostasis. Indeed a patchy inflammation affecting both the exocrine and endocrine pancreas has frequently been reported in subjects with Type 1 diabetes [14–17].

Possible limitations of our study are the relatively low numbers of biopsies available from subjects with newly diagnosed Type 1 diabetes. However, it is well established that this type of biopsies remains rare. Another point of consideration is that the IHC staining allows detailed analysis of the cellular expression pattern of a specific protein, but it is not optimal in quantifying the exact amount of protein. However, for proteins with posttranslational modifications, e.g. defensins, alternative quantitative techniques such as in situ hybridization are not applicable.

Collectively, presented findings implicate a disturbance in the innate immune response in subjects with Type 1 diabetes. Reduced or even lack of expression of defensins could cause prolonged and exaggerated inflammation and dysregulation of the bridge to the adaptive immune responses [7, 24]. A similar reduced expression of defensins has been seen in other inflammatory diseases [4, 7]. The findings presented support an important role for defensins in Type 1 diabetes and further studies on the role of the innate immune system in Type 1 diabetes is needed.

Abbreviations

DiViD Diabetes virus detection

FFPE Formalin-fixed paraffin-embedded

IF Immunofluorescence

IHC Immunohistochemistry

mAb Monoclonal antibody

HbD-1 Human beta defensin 1

Author contributions

A.T., S.I., L.K, K.D-J, and O.K designed, analyzed and interpreted the study and wrote the manuscript. O.K. is the guarantors of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The results were in part presented in a lecture at the SSSD Conference Iceland 12–13 may 2022.

The data sets generated during the current study are available from the corresponding author upon reasonable request.

Funding

Open access funding provided by Uppsala University. This study was supported by grants from the Swedish Medical Research Council (2019–01415) Novo Nordisk Foundation, the Ernfors Family Fund, Nils Eric Holmstens forskningsstiftelse, Barndiabetesfonden, Diabetesfonden and the Sten A Olssons Foundation. Human pancreatic islets were obtained from The Nordic network for Clinical islet Transplantation, supported by the Swedish national strategic research initiative EXODIAB (Excellence Of Diabetes Research in Sweden), Helmsley Charitable Trust and the Juvenile Diabetes Research Foundation.

Data availability

The data sets generated during the current study are available from the corresponding author upon reasonable request

Declarations

Conflict of interest

The authors have nothing to disclose.

Ethical Standard Statement

Consent for organ donation (for clinical transplantation and for use in research) was obtained via online database (https://www.socialstyrelsen.se/en/apply-and-register/join-the-swedish-nationaldonor-register/) or verbally from the deceased’s next of kin by the attending physician and documented in the medical records of the deceased in accordance with Swedish law and as approved by the Swedish Ethical Review Authority (Dnr 2023-01845-01). All tissue included in the study was procured, stored and analyzed as approved by the Regional Ethics Committee in Uppsala (Dnr: 2015/444). Collection of pancreatic tissue in the DiViD study was approved by the Norwegian Governments Regional Ethics Committee.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Lehrer RI Lu W α-Defensins in human innate immunity Immunol Rev 2012 245 1 84 112 10.1111/j.1600-065X.2011.01082.x 22168415
Lehrer RI, Lu W (2012) α-Defensins in human innate immunity. Immunol Rev 245(1):84–11222168415 10.1111/j.1600-065X.2011.01082.x
2. Pazgier M Li X Lu W Lubkowski J Human defensins: synthesis and structural properties Curr Pharm Des 2007 13 30 3096 3118 10.2174/138161207782110381 17979752
Pazgier M, Li X, Lu W, Lubkowski J (2007) Human defensins: synthesis and structural properties. Curr Pharm Des 13(30):3096–311817979752 10.2174/138161207782110381
3. Zhao L Lu W Defensins in innate immunity Curr Opin Hematol 2014 21 1 37 42 10.1097/MOH.0000000000000005 24275690
Zhao L, Lu W (2014) Defensins in innate immunity. Curr Opin Hematol 21(1):37–4224275690 10.1097/MOH.0000000000000005
4. Nakamura K Sakurigon N Takakuwa A Ayabe T Paneth cell α-defensins and enteric microbiota in health and disease Biosci Microbiota Food Health 2016 35 2 57 67 10.12938/bmfh.2015-019 27200259
Nakamura K, Sakurigon N, Takakuwa A, Ayabe T (2016) Paneth cell α-defensins and enteric microbiota in health and disease. Biosci Microbiota Food Health 35(2):57–6727200259 10.12938/bmfh.2015-019
5. Xu D Lu W Defensins: a double-edged sword in host immunity Front Immunol 2020 11 764 10.3389/fimmu.2020.00764 32457744
Xu D, Lu W (2020) Defensins: a double-edged sword in host immunity. Front Immunol 11:76432457744 10.3389/fimmu.2020.00764
6. Zhao C Wang I Lehrer RI Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells FEBS Lett 1996 396 2–3 319 322 10.1016/0014-5793(96)01123-4 8915011
Zhao C, Wang I, Lehrer RI (1996) Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 396(2–3):319–3228915011 10.1016/0014-5793(96)01123-4
7. Koeninger L Armbruster NS Brinch KS Human β-defensin 2 mediated immune modulation as treatment for experimental colitis Front Immunol 2020 31 11 93 10.3389/fimmu.2020.00093
Koeninger L, Armbruster NS, Brinch KS et al (2020) Human β-defensin 2 mediated immune modulation as treatment for experimental colitis. Front Immunol 31(11):9310.3389/fimmu.2020.00093
8. Yang D Chertov O Bykovskaia SN β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 Science 1999 286 5439 525 528 10.1126/science.286.5439.525 10521347
Yang D, Chertov O, Bykovskaia SN et al (1999) β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286(5439):525–52810521347 10.1126/science.286.5439.525
9. Joly S Maze C McCray PB Guthmiller JM Human β-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms J Clin Microbiol 2004 42 3 1024 1029 10.1128/JCM.42.3.1024-1029.2004 15004048
Joly S, Maze C, McCray PB, Guthmiller JM (2004) Human β-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 42(3):1024–102915004048 10.1128/JCM.42.3.1024-1029.2004
10. Kanda N Kamata M Tada Y Ishikawa T Sato S Watanabe S Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells J Leukoc Biol 2011 89 6 935 944 10.1189/jlb.0111004 21367976
Kanda N, Kamata M, Tada Y, Ishikawa T, Sato S, Watanabe S (2011) Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells. J Leukoc Biol 89(6):935–94421367976 10.1189/jlb.0111004
11. Machado LR Ottolini B An evolutionary history of defensins: a role for copy number variation in maximizing host innate and adaptive immune responses Front Immunol 2015 18 6 115
Machado LR, Ottolini B (2015) An evolutionary history of defensins: a role for copy number variation in maximizing host innate and adaptive immune responses. Front Immunol 18(6):115
12. Stenwall A Ingvast S Skog O Korsgren O Characterization of host defense molecules in the human pancreas Islets 2019 11 4 89 101 10.1080/19382014.2019.1585165 31242128
Stenwall A, Ingvast S, Skog O, Korsgren O (2019) Characterization of host defense molecules in the human pancreas. Islets 11(4):89–10131242128 10.1080/19382014.2019.1585165
13. Schnapp D Reid CJ Harris A Localization of expression of human beta defensin-1 in the pancreas and kidney J Pathol 1998 186 1 99 103 10.1002/(SICI)1096-9896(199809)186:1<99::AID-PATH133>3.0.CO;2-# 9875146
Schnapp D, Reid CJ, Harris A (1998) Localization of expression of human beta defensin-1 in the pancreas and kidney. J Pathol 186(1):99–1039875146 10.1002/(SICI)1096-9896(199809)186:1<99::AID-PATH133>3.0.CO;2-#
14. Gepts W Pathologic anatomy of the pancreas in juvenile diabetes mellitus Diabetes 1965 14 10 619 633 10.2337/diab.14.10.619 5318831
Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14(10):619–6335318831 10.2337/diab.14.10.619
15. Gaglia JL Harisinghani M Aganj I Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients Proc Natl Acad Sci 2015 112 7 2139 2144 10.1073/pnas.1424993112 25650428
Gaglia JL, Harisinghani M, Aganj I et al (2015) Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. Proc Natl Acad Sci 112(7):2139–214425650428 10.1073/pnas.1424993112
16. Coppieters KT Dotta F Amirian N Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients J Exp Med 2012 209 1 51 60 10.1084/jem.20111187 22213807
Coppieters KT, Dotta F, Amirian N et al (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209(1):51–6022213807 10.1084/jem.20111187
17. Korsgren S Molin Y Salmela K Lundgren T Melhus Å Korsgren O On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response Am J Pathol 2012 181 5 1735 1748 10.1016/j.ajpath.2012.07.022 22944599
Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus Å, Korsgren O (2012) On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am J Pathol 181(5):1735–174822944599 10.1016/j.ajpath.2012.07.022
18. Cerqueiro Bybrant M Grahnquist L Örtqvist E Tissue transglutaminase autoantibodies in children with newly diagnosed type 1 diabetes are related to human leukocyte antigen but not to islet autoantibodies: a Swedish nationwide prospective population-based cohort study Autoimmunity 2018 51 5 221 227 10.1080/08916934.2018.1494160 30444426
Cerqueiro Bybrant M, Grahnquist L, Örtqvist E et al (2018) Tissue transglutaminase autoantibodies in children with newly diagnosed type 1 diabetes are related to human leukocyte antigen but not to islet autoantibodies: a Swedish nationwide prospective population-based cohort study. Autoimmunity 51(5):221–22730444426 10.1080/08916934.2018.1494160
19. Angie T Sofie I Åsa M Oskar S Olle K A decisive bridge between innate immunity and the pathognomonic morphological characteristics of type 1 diabetes demonstrated by instillation of heat-inactivated bacteria in the pancreatic duct of rats Acta Diabetol 2022 59 8 1011 1018 10.1007/s00592-022-01881-4 35461380
Angie T, Sofie I, Åsa M, Oskar S, Olle K (2022) A decisive bridge between innate immunity and the pathognomonic morphological characteristics of type 1 diabetes demonstrated by instillation of heat-inactivated bacteria in the pancreatic duct of rats. Acta Diabetol 59(8):1011–101835461380 10.1007/s00592-022-01881-4
20. de Goffau MC Luopajärvi K Knip M Fecal microbiota composition differs between children with β-cell autoimmunity and those without Diabetes 2013 62 4 1238 1244 10.2337/db12-0526 23274889
de Goffau MC, Luopajärvi K, Knip M et al (2013) Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 62(4):1238–124423274889 10.2337/db12-0526
21. Bosi E Molteni L Radaelli MG Increased intestinal permeability precedes clinical onset of type 1 diabetes Diabetologia 2006 49 12 2824 2827 10.1007/s00125-006-0465-3 17028899
Bosi E, Molteni L, Radaelli MG et al (2006) Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49(12):2824–282717028899 10.1007/s00125-006-0465-3
22. Krogvold L Edwin B Buanes T Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study Diabetologia 2014 57 4 841 843 10.1007/s00125-013-3155-y 24429579
Krogvold L, Edwin B, Buanes T et al (2014) Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 57(4):841–84324429579 10.1007/s00125-013-3155-y
23. Barnea M Madar Z Froy O Glucose and insulin are needed for optimal defensin expression in human cell lines Biochem Biophys Res Commun 2008 367 2 452 456 10.1016/j.bbrc.2007.12.158 18178160
Barnea M, Madar Z, Froy O (2008) Glucose and insulin are needed for optimal defensin expression in human cell lines. Biochem Biophys Res Commun 367(2):452–45618178160 10.1016/j.bbrc.2007.12.158
24. Diamond G Kaiser V Rhodes J Russell JP Bevins CL Transcriptional regulation of β-defensin gene expression in tracheal epithelial cells Infect Immun 2000 68 1 113 119 10.1128/IAI.68.1.113-119.2000 10603376
Diamond G, Kaiser V, Rhodes J, Russell JP, Bevins CL (2000) Transcriptional regulation of β-defensin gene expression in tracheal epithelial cells. Infect Immun 68(1):113–11910603376 10.1128/IAI.68.1.113-119.2000
25. Page RA Malik AN Elevated levels of beta defensin-1 mRNA in diabetic kidneys of GK rats Biochem Biophys Res Commun 2003 310 2 513 521 10.1016/j.bbrc.2003.09.034 14521940
Page RA, Malik AN (2003) Elevated levels of beta defensin-1 mRNA in diabetic kidneys of GK rats. Biochem Biophys Res Commun 310(2):513–52114521940 10.1016/j.bbrc.2003.09.034
26. Wehkamp J Salzman NH Porter E Reduced Paneth cell α-defensins in ileal Crohn’s disease Proc Natl Acad Sci U S A 2005 102 50 18129 18134 10.1073/pnas.0505256102 16330776
Wehkamp J, Salzman NH, Porter E et al (2005) Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc Natl Acad Sci U S A 102(50):18129–1813416330776 10.1073/pnas.0505256102
27. Kościuczuk EM Lisowski P Jarczak J Cathelicidins: family of antimicrobial peptides. A review Mol Biol Rep 2012 39 12 10957 10970 10.1007/s11033-012-1997-x 23065264
Kościuczuk EM, Lisowski P, Jarczak J et al (2012) Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep 39(12):10957–1097023065264 10.1007/s11033-012-1997-x
28. Dürr UHN Sudheendra US Ramamoorthy A LL-37, the only human member of the cathelicidin family of antimicrobial peptides Biochim Biophys Acta (BBA) Biomembr 2006 1758 9 1408 1425 10.1016/j.bbamem.2006.03.030
Dürr UHN, Sudheendra US, Ramamoorthy A (2006) LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta (BBA) Biomembr 1758(9):1408–142510.1016/j.bbamem.2006.03.030
29. Acen EL Biraro IA Worodria W Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: a systematic review and meta-analysis PLoS ONE 2021 16 6 e0252762 10.1371/journal.pone.0252762 34115790
Acen EL, Biraro IA, Worodria W et al (2021) Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: a systematic review and meta-analysis. PLoS ONE 16(6):e025276234115790 10.1371/journal.pone.0252762
30. Mathieu C Badenhoop K Vitamin D and type 1 diabetes mellitus: state of the art Trends Endocrinol Metab 2005 16 6 261 266 10.1016/j.tem.2005.06.004 15996876
Mathieu C, Badenhoop K (2005) Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 16(6):261–26615996876 10.1016/j.tem.2005.06.004
31. Hou Y Song A Jin Y Xia Q Song G Xing X A dose–response meta-analysis between serum concentration of 25-hydroxy vitamin D and risk of type 1 diabetes mellitus Eur J Clin Nutr 2021 75 7 1010 1023 10.1038/s41430-020-00813-1 33235321
Hou Y, Song A, Jin Y, Xia Q, Song G, Xing X (2021) A dose–response meta-analysis between serum concentration of 25-hydroxy vitamin D and risk of type 1 diabetes mellitus. Eur J Clin Nutr 75(7):1010–102333235321 10.1038/s41430-020-00813-1
32. Chen S Sims GP Chen XX Gu YY Chen S Lipsky PE Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation J Immunol 2007 179 3 1634 1647 10.4049/jimmunol.179.3.1634 17641030
Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE (2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179(3):1634–164717641030 10.4049/jimmunol.179.3.1634
33. Savastio S Cadario F Genoni G Vitamin D deficiency and glycemic status in children and adolescents with type 1 diabetes mellitus PLoS ONE 2016 11 9 e0162554 10.1371/journal.pone.0162554 27607348
Savastio S, Cadario F, Genoni G et al (2016) Vitamin D deficiency and glycemic status in children and adolescents with type 1 diabetes mellitus. PLoS ONE 11(9):e016255427607348 10.1371/journal.pone.0162554
34. Guo J Fu W Immune regulation of islet homeostasis and adaptation J Mol Cell Biol 2020 12 10 764 774 10.1093/jmcb/mjaa009 32236479
Guo J, Fu W (2020) Immune regulation of islet homeostasis and adaptation. J Mol Cell Biol 12(10):764–77432236479 10.1093/jmcb/mjaa009
35. Cui W De Jesus K Zhao H Overexpression of Reg3α increases cell growth and the levels of cyclin D1 and CDK4 in insulinoma cells Growth Factors 2009 27 3 195 202 10.1080/08977190902863548 19343564
Cui W, De Jesus K, Zhao H et al (2009) Overexpression of Reg3α increases cell growth and the levels of cyclin D1 and CDK4 in insulinoma cells. Growth Factors 27(3):195–20219343564 10.1080/08977190902863548
36. Ding Y Xu Y Shuai X Reg3α overexpression protects pancreatic β cells from cytokine-induced damage and improves islet transplant outcome Mol Med 2014 20 1 548 558 10.2119/molmed.2014.00104
Ding Y, Xu Y, Shuai X et al (2014) Reg3α overexpression protects pancreatic β cells from cytokine-induced damage and improves islet transplant outcome. Mol Med 20(1):548–55810.2119/molmed.2014.00104
37. Yu L Li L Liu J Recombinant Reg3α prevents Islet β-cell apoptosis and promotes β-cell regeneration Int J Mol Sci 2022 23 18 10584 10.3390/ijms231810584 36142497
Yu L, Li L, Liu J et al (2022) Recombinant Reg3α prevents Islet β-cell apoptosis and promotes β-cell regeneration. Int J Mol Sci 23(18):1058436142497 10.3390/ijms231810584
